Effects of Oral Peppermint Supplementation on Cardiometabolic Parameters
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Systolic blood pressure
研究概览
简要总结
Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. Previous non-randomized interventions have shown that oral peppermint may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.
Therefore, the primary purpose of the proposed investigation is to test the ability of oral peppermint oil supplementation to improve cardiometabolic parameters in healthy individuals.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Between 18 & 65 years
- •Non-smoker
- •BMI < 30
- •Able to give informed consent
排除标准
- •Pregnancy
- •Diabetes or any other metabolic/ uncontrolled hypertensive conditions
- •Food allergies to peppermint
- •Habitual consumption of peppermint
- •Not regularly taking medication or antioxidant supplements
研究组 & 干预措施
Placebo
Identical in taste and colour to the supplement juice, but with no peppermint content.
干预措施: Placebo (Other)
Peppermint oil
50 uL of peppermint oil, which will be diluted with 100 mL of water - taken twice per day.
干预措施: Peppermint oil. (Dietary Supplement)
结局指标
主要结局
Systolic blood pressure
时间窗: 20 days
Systolic blood pressure - measured using a digital blood pressure monitor
Systolic blood pressure
时间窗: Baseline
Systolic blood pressure - measured using a digital blood pressure monitor
次要结局
- Diastolic blood pressure(20 days)
- Resting utilization of fats(20 days)
- Blood glucose(20 days)
- Triglyceride glucose index(20 days)
- Blood triglycerides(20 days)
- Percent bodyfat(20 days)
- Waist to hip ratio(Baseline)
- Resting metabolic rate(20 days)
- Resting utilization of carbohydrates(Baseline)
- Blood cholesterol (Total, HDL & LDL)(20 days)
- Blood haemoglobin(20 days)
- Coop-Wonka chart(20 days)
- Beck Depression Inventory(20 days)
- State Trait Anxiety Inventory(20 days)
- Insomnia Severity Index(Baseline)
- Pittsburgh Sleep Quality Index(20 days)
- Epworth Sleepiness Scale(20 days)
- Percent bodyfat(Baseline)
- Waist to hip ratio(20 days)
- Resting metabolic rate(Baseline)
- Resting utilization of carbohydrates(20 days)
- Blood glucose(Baseline)
- Resting utilization of fats(Baseline)
- Triglyceride glucose index(Baseline)
- Blood triglycerides(Baseline)
- Blood cholesterol (Total, HDL & LDL)(Baseline)
- Blood haemoglobin(Baseline)
- Coop-Wonka chart(Baseline)
- Beck Depression Inventory(Baseline)
- State Trait Anxiety Inventory(Baseline)
- Insomnia Severity Index(20 days)
- Pittsburgh Sleep Quality Index(Baseline)
- Epworth Sleepiness Scale(Baseline)
- Diastolic blood pressure(Baseline)
研究者
Jonathan Sinclair
Professor
University of Central Lancashire